Profilin-1 (Pfn-1) is a ubiquitously expressed actin-binding protein that is essential for normal cell proliferation and migration. In breast cancer and several other adenocarcinomas, Pfn-1 expression is downregulated when compared to normal tissues. Previous studies from our laboratory have shown that genetically modulating Pfn-1 expression significantly impacts proliferation, migration, and invasion of breast cancer cells in vitro, and mammary tumor growth, dissemination, and metastatic colonization in vivo. Therefore, small molecules that can modulate Pfn-1 expression could have therapeutic potential in the treatment of metastatic breast cancer. The overall goal of this study was to perform a multiplexed phenotypic screen to identify compounds that inhibit cell motility through upregulation of Pfn-1. Screening of a test cassette of 1280 compounds with known biological activities on an Oris？ Pro 384 cell migration platform identified several agents that increased Pfn-1 expression greater than two-fold over vehicle controls and exerted anti-migratory effects in the absence of overt cytotoxicity in MDA-MB-231 human breast cancer cells. Concentration-response confirmation and orthogonal follow-up assays identified two bona fide inducers of Pfn-1, purvalanol and tyrphostin A9, that confirmed in single-cell motility assays and Western blot analyses. SiRNA-mediated knockdown of Pfn-1 abrogated the inhibitory effect of tyrphostin A9 on cell migration, suggesting Pfn-1 is mechanistically linked to tyrphostin A9′s anti-migratory activity. The data illustrate the utility of the high-content cell motility assay to discover novel targeted anti-migratory agents by integrating functional phenotypic analyses with target-specific readouts in a single assay platform.
References
[1]
Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331: 1559–1564. doi: 10.1126/science.1203543
[2]
Eckhardt BL, Francis PA, Parker BS, Anderson RL (2012) Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov 11: 479–497. doi: 10.1038/nrd2372
[3]
Hulkower KI, Herber RL (2011) Cell Migration and Invasion Assays as Tools for Drug Discovery. Pharmaceutics 3: 107–124. doi: 10.3390/pharmaceutics3010107
[4]
Yarrow JC, Perlman ZE, Westwood NJ, Mitchison TJ (2004) A high-throughput cell migration assay using scratch wound healing, a comparison of image-based readout methods. BMC Biotechnol 4: 21.
[5]
Kam Y, Guess C, Estrada L, Weidow B, Quaranta V (2008) A novel circular invasion assay mimics in vivo invasive behavior of cancer cell lines and distinguishes single-cell motility in vitro. BMC Cancer 8: 198. doi: 10.1186/1471-2407-8-198
[6]
Gough W, Hulkower KI, Lynch R, McGlynn P, Uhlik M, et al. (2011) A quantitative, facile, and high-throughput image-based cell migration method is a robust alternative to the scratch assay. J Biomol Screen 16: 155–163. doi: 10.1177/1087057110393340
[7]
Ding Z, Roy P (2013) Profilin-1 versus profilin-2: two faces of the same coin? Breast Cancer Res 15: 311. doi: 10.1186/bcr3433
[8]
Ding Z, Gau D, Deasy B, Wells A, Roy P (2009) Both actin and polyproline interactions of profilin-1 are required for migration, invasion and capillary morphogenesis of vascular endothelial cells. Exp Cell Res 315: 2963–2973. doi: 10.1016/j.yexcr.2009.07.004
[9]
Ding Z, Lambrechts A, Parepally M, Roy P (2006) Silencing profilin-1 inhibits endothelial cell proliferation, migration and cord morphogenesis. J Cell Sci 119: 4127–4137. doi: 10.1242/jcs.03268
[10]
Khadka DK, Liu W, Habas R (2009) Non-redundant roles for Profilin2 and Profilin1 during vertebrate gastrulation. Dev Biol 332: 396–406. doi: 10.1016/j.ydbio.2009.06.008
[11]
Kullmann JA, Neumeyer A, Gurniak CB, Friauf E, Witke W, et al. (2012) Profilin1 is required for glial cell adhesion and radial migration of cerebellar granule neurons. EMBO Rep 13: 75–82. doi: 10.1038/embor.2011.211
[12]
Sato A, Khadka DK, Liu W, Bharti R, Runnels LW, et al. (2006) Profilin is an effector for Daam1 in non-canonical Wnt signaling and is required for vertebrate gastrulation. Development 133: 4219–4231. doi: 10.1242/dev.02590
[13]
Verheyen EM, Cooley L (1994) Profilin mutations disrupt multiple actin-dependent processes during Drosophila development. Development 120: 717–728.
[14]
Ding Z, Joy M, Bhargava R, Gunsaulus M, Lakshman N, et al.. (2013) Profilin-1 downregulation has contrasting effects on early vs late steps of breast cancer metastasis. Oncogene 2013 May 20. doi: 10.1038/onc.2013.166. [Epub ahead of print].
[15]
Zou L, Jaramillo M, Whaley D, Wells A, Panchapakesa V, et al. (2007) Profilin-1 is a negative regulator of mammary carcinoma aggressiveness. Br J Cancer 97: 1361–1371.
[16]
Roy P, Jacobson K (2004) Overexpression of profilin reduces the migration of invasive breast cancer cells. Cell Motil Cytoskeleton 57: 84–95. doi: 10.1002/cm.10160
[17]
Janke J, Schluter K, Jandrig B, Theile M, Kolble K, et al. (2000) Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin 1. J Exp Med 191: 1675–1686. doi: 10.1084/jem.191.10.1675
[18]
Wittenmayer N, Jandrig B, Rothkegel M, Schluter K, Arnold W, et al. (2004) Tumor suppressor activity of profilin requires a functional actin binding site. Mol Biol Cell 15: 1600–1608. doi: 10.1091/mbc.e03-12-0873
[19]
Iversen PW, Beck B, Chen YF, Dere W, Devanarayan V, et al.. (2004) HTS Assay Validation. In: Sittampalam GS, Gal-Edd N, Arkin M, Auld D, Austin C et al.., editors. Assay Guidance Manual. Bethesda (MD).
[20]
Vogt A, Lazo JS (2007) Implementation of high-content assay for inhibitors of mitogen-activated protein kinase phosphatases. Methods 42: 268–277. doi: 10.1016/j.ymeth.2007.02.006
[21]
Vogt A (2010) Advances in two-dimensional cell migration technologies. European Pharmaceutical Review 15: 26–29.
[22]
Bae YH, Ding Z, Zou L, Wells A, Gertler F, et al. (2009) Loss of profilin-1 expression enhances breast cancer cell motility by Ena/VASP proteins. J Cell Physiol 219: 354–364. doi: 10.1002/jcp.21677
[23]
Bae YH, Ding Z, Das T, Wells A, Gertler F, et al. (2010) Profilin1 regulates PI(3,4)P2 and lamellipodin accumulation at the leading edge thus influencing motility of MDA-MB-231 cells. Proc Natl Acad Sci U S A 107: 21547–21552. doi: 10.1073/pnas.1002309107
[24]
Quintavalle M, Elia L, Price JH, Heynen-Genel S, Courtneidge SA (2011) A cell-based high-content screening assay reveals activators and inhibitors of cancer cell invasion. Sci Signal 4: ra49. doi: 10.1126/scisignal.2002032
[25]
Bilder GE, Krawiec JA, McVety K, Gazit A, Gilon C, et al. (1991) Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am J Physiol 260: C721–730.
[26]
Stringa E, Knauper V, Murphy G, Gavrilovic J (2000) Collagen degradation and platelet-derived growth factor stimulate the migration of vascular smooth muscle cells. J Cell Sci 113 (Pt 11): 2055–2064.
[27]
Vollmer LL, Jimenez M, Camarco DP, Zhu W, Daghestani HN, et al. (2011) A simplified synthesis of novel dictyostatin analogues with in vitro activity against epothilone B-resistant cells and antiangiogenic activity in zebrafish embryos. Mol Cancer Ther 10: 994–1006. doi: 10.1158/1535-7163.mct-10-1048
[28]
Vogt A, McDonald PR, Tamewitz A, Sikorski RP, Wipf P, et al. (2008) A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. Mol Cancer Ther 7: 330–340. doi: 10.1158/1535-7163.mct-07-2165
[29]
Campbell PM, Der CJ (2004) Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 14: 105–114. doi: 10.1016/j.semcancer.2003.09.015
[30]
Tarcic G, Yarden Y (2010) MAP Kinase activation by receptor tyrosine kinases: in control of cell migration. Methods Mol Biol 661: 125–135. doi: 10.1007/978-1-60761-795-2_7
[31]
Gardel ML, Schneider IC, Aratyn-Schaus Y, Waterman CM (2010) Mechanical integration of actin and adhesion dynamics in cell migration. Annu Rev Cell Dev Biol 26: 315–333. doi: 10.1146/annurev.cellbio.011209.122036
[32]
Entschladen F, Lang K, Drell TL, Joseph J, Zaenker KS (2002) Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunol Immunother 51: 467–482. doi: 10.1007/s00262-002-0300-8
[33]
Pai VP, Marshall AM, Hernandez LL, Buckley AR, Horseman ND (2009) Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival. Breast Cancer Res 11: R81. doi: 10.1186/bcr2448
[34]
Kapoor N, Bartoszewski R, Qadri YJ, Bebok Z, Bubien JK, et al. (2009) Knockdown of ASIC1 and epithelial sodium channel subunits inhibits glioblastoma whole cell current and cell migration. J Biol Chem 284: 24526–24541. doi: 10.1074/jbc.m109.037390
[35]
Al-Ghoul M, Valdes R Jr (2008) Mammalian cardenolides in cancer prevention and therapeutics. Ther Drug Monit 30: 234–238. doi: 10.1097/ftd.0b013e31816b90ff
